Procarta获得150万欧元资助用于新型抗生素的研发以抗击抗菌素耐药性

2019-03-06 不详 MedSci原创

Procarta Biosystems宣布从Novo Holdings REPAIR Impact Fund获得150万欧元的资助,以支持开发抗击抗菌药物的新型疗法(AMR)。新的资助将用于开发Procarta基于寡核苷酸的抗菌平台的全新一类抗生素精准药物。

Procarta Biosystems宣布从Novo Holdings REPAIR Impact Fund获得150万欧元的资助,以支持开发抗击抗菌药物的新型疗法(AMR)。新的资助将用于开发Procarta基于寡核苷酸的抗菌平台的全新一类抗生素精准药物。

Procarta的PRO-202正在进行临床前开发,以治疗复杂的尿路感染(cUTI)和复杂的腹腔内感染(cIAI)。抗生素无效(REPAIR)病原体(屎肠球菌、金黄色葡萄球菌、肺炎克雷伯菌、鲍曼不动杆菌、铜绿假单胞菌和肠杆菌科属)是全世界大部分cUTI和cIAI的原因。

特别值得注意的是耐碳青霉烯的肠杆菌科(CRE),一种对碳青霉烯类抗菌素具有抗性的革兰氏阴性菌的亚组。CRE通常被认为是最可怕的新"超级细菌",这些细菌可以杀死多达一半的患有这些病原体血流感染的患者。令人担忧的是,碳青霉烯类抗药性在2004年至2008年期间呈指数增长。

Procarta首席执行官Andrew Lightfoot博士评论道:"在Procarta,我们认为现在是时候探索新的模式和目标,以促成抗菌研究的转变。我们很高兴REPAIR Impact Fund认识到Procarta新颖方法的潜力并支持了我们的研发。"

REPAIR影响基金主任Aleks Engel博士评论说:"Procarta的转录因子诱饵平台正是我们希望能够找到的新型模式。我们认为该技术具有巨大的潜力,可作为传染病及其他新疗法开发新方法的基础。"

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1676870, encodeId=972116e6870ac, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Sat Dec 07 09:52:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927930, encodeId=16e7192e93071, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Oct 21 13:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976990, encodeId=cd8619e6990dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Oct 31 08:52:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774898, encodeId=9e061e7489850, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Wed Mar 20 06:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016207, encodeId=1f31201620ecd, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Thu Aug 29 05:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300246, encodeId=d149130024603, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330806, encodeId=35b1133080698, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357126, encodeId=3d35135e12682, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477260, encodeId=8a4c14e72609a, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4114, encryptionId=429a41149d, topicName=cART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46987366013, createdName=ms2999106592497887, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602129, encodeId=d67b16021297b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1676870, encodeId=972116e6870ac, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Sat Dec 07 09:52:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927930, encodeId=16e7192e93071, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Oct 21 13:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976990, encodeId=cd8619e6990dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Oct 31 08:52:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774898, encodeId=9e061e7489850, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Wed Mar 20 06:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016207, encodeId=1f31201620ecd, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Thu Aug 29 05:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300246, encodeId=d149130024603, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330806, encodeId=35b1133080698, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357126, encodeId=3d35135e12682, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477260, encodeId=8a4c14e72609a, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4114, encryptionId=429a41149d, topicName=cART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46987366013, createdName=ms2999106592497887, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602129, encodeId=d67b16021297b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=)]
    2019-10-21 smlt2008
  3. [GetPortalCommentsPageByObjectIdResponse(id=1676870, encodeId=972116e6870ac, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Sat Dec 07 09:52:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927930, encodeId=16e7192e93071, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Oct 21 13:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976990, encodeId=cd8619e6990dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Oct 31 08:52:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774898, encodeId=9e061e7489850, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Wed Mar 20 06:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016207, encodeId=1f31201620ecd, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Thu Aug 29 05:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300246, encodeId=d149130024603, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330806, encodeId=35b1133080698, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357126, encodeId=3d35135e12682, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477260, encodeId=8a4c14e72609a, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4114, encryptionId=429a41149d, topicName=cART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46987366013, createdName=ms2999106592497887, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602129, encodeId=d67b16021297b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=)]
    2019-10-31 linlin2312
  4. [GetPortalCommentsPageByObjectIdResponse(id=1676870, encodeId=972116e6870ac, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Sat Dec 07 09:52:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927930, encodeId=16e7192e93071, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Oct 21 13:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976990, encodeId=cd8619e6990dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Oct 31 08:52:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774898, encodeId=9e061e7489850, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Wed Mar 20 06:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016207, encodeId=1f31201620ecd, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Thu Aug 29 05:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300246, encodeId=d149130024603, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330806, encodeId=35b1133080698, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357126, encodeId=3d35135e12682, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477260, encodeId=8a4c14e72609a, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4114, encryptionId=429a41149d, topicName=cART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46987366013, createdName=ms2999106592497887, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602129, encodeId=d67b16021297b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1676870, encodeId=972116e6870ac, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Sat Dec 07 09:52:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927930, encodeId=16e7192e93071, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Oct 21 13:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976990, encodeId=cd8619e6990dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Oct 31 08:52:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774898, encodeId=9e061e7489850, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Wed Mar 20 06:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016207, encodeId=1f31201620ecd, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Thu Aug 29 05:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300246, encodeId=d149130024603, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330806, encodeId=35b1133080698, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357126, encodeId=3d35135e12682, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477260, encodeId=8a4c14e72609a, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4114, encryptionId=429a41149d, topicName=cART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46987366013, createdName=ms2999106592497887, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602129, encodeId=d67b16021297b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1676870, encodeId=972116e6870ac, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Sat Dec 07 09:52:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927930, encodeId=16e7192e93071, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Oct 21 13:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976990, encodeId=cd8619e6990dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Oct 31 08:52:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774898, encodeId=9e061e7489850, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Wed Mar 20 06:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016207, encodeId=1f31201620ecd, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Thu Aug 29 05:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300246, encodeId=d149130024603, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330806, encodeId=35b1133080698, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357126, encodeId=3d35135e12682, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477260, encodeId=8a4c14e72609a, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4114, encryptionId=429a41149d, topicName=cART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46987366013, createdName=ms2999106592497887, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602129, encodeId=d67b16021297b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=)]
    2019-03-08 lqvr
  7. [GetPortalCommentsPageByObjectIdResponse(id=1676870, encodeId=972116e6870ac, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Sat Dec 07 09:52:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927930, encodeId=16e7192e93071, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Oct 21 13:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976990, encodeId=cd8619e6990dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Oct 31 08:52:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774898, encodeId=9e061e7489850, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Wed Mar 20 06:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016207, encodeId=1f31201620ecd, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Thu Aug 29 05:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300246, encodeId=d149130024603, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330806, encodeId=35b1133080698, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357126, encodeId=3d35135e12682, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477260, encodeId=8a4c14e72609a, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4114, encryptionId=429a41149d, topicName=cART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46987366013, createdName=ms2999106592497887, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602129, encodeId=d67b16021297b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1676870, encodeId=972116e6870ac, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Sat Dec 07 09:52:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927930, encodeId=16e7192e93071, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Oct 21 13:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976990, encodeId=cd8619e6990dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Oct 31 08:52:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774898, encodeId=9e061e7489850, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Wed Mar 20 06:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016207, encodeId=1f31201620ecd, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Thu Aug 29 05:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300246, encodeId=d149130024603, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330806, encodeId=35b1133080698, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357126, encodeId=3d35135e12682, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477260, encodeId=8a4c14e72609a, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4114, encryptionId=429a41149d, topicName=cART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46987366013, createdName=ms2999106592497887, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602129, encodeId=d67b16021297b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=)]
    2019-03-08 zhaojie88
  9. [GetPortalCommentsPageByObjectIdResponse(id=1676870, encodeId=972116e6870ac, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Sat Dec 07 09:52:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927930, encodeId=16e7192e93071, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Oct 21 13:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976990, encodeId=cd8619e6990dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Oct 31 08:52:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774898, encodeId=9e061e7489850, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Wed Mar 20 06:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016207, encodeId=1f31201620ecd, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Thu Aug 29 05:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300246, encodeId=d149130024603, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330806, encodeId=35b1133080698, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357126, encodeId=3d35135e12682, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477260, encodeId=8a4c14e72609a, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4114, encryptionId=429a41149d, topicName=cART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46987366013, createdName=ms2999106592497887, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602129, encodeId=d67b16021297b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1676870, encodeId=972116e6870ac, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Sat Dec 07 09:52:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927930, encodeId=16e7192e93071, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Oct 21 13:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976990, encodeId=cd8619e6990dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Oct 31 08:52:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774898, encodeId=9e061e7489850, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Wed Mar 20 06:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016207, encodeId=1f31201620ecd, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Thu Aug 29 05:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300246, encodeId=d149130024603, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330806, encodeId=35b1133080698, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357126, encodeId=3d35135e12682, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477260, encodeId=8a4c14e72609a, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4114, encryptionId=429a41149d, topicName=cART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46987366013, createdName=ms2999106592497887, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602129, encodeId=d67b16021297b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Mar 08 09:52:00 CST 2019, time=2019-03-08, status=1, ipAttribution=)]
    2019-03-08 sunylz

相关资讯

J Control Release: 在去势难治性前列腺癌中,脂质与寡核苷酸偶联可以提高细胞吞噬和反义-TCTP的效率

翻译控制肿瘤蛋白(TCTP)与细胞生长、细胞周期进程、恶性转化和细胞凋亡的抑制等大量重要细胞学过程相关。因此,TCTP是一个目前被作为一个潜在的治疗几种癌症的靶点,包括前列腺癌、乳腺癌和肺癌。之前,有报道指出,TCTP在去势难治性前列腺癌中(CRPC)是超表达的,并且与治疗的抵抗性有关系。最近,研究人员开发了TCTP反义寡核苷酸链(ASOs)来尝试抑制TCTP的表达。然而,这些ASOs的细胞内传递